Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
